Healthcare & Life Sciences Blog -

United States: President Trump Tariffs on Patented Pharmaceuticals Under Section 232

by Patrick de Lapérouse, Jane E. Hobson, Oren Livne, Lois Sheng Liu, Chandri Navarro, Eunkyung Kim Shin, Christine Streatfeild, Randall B. Sunberg, Xin Tao and Lise S. Test

Pharmaceuticals & Biotech

The US BIOSECURE Act Becomes Law: Implications for Collaborations with “Biotechnology Companies of Concern”

by Janet K. Kim, Xin Tao, Lise S. Test and Bruce J. Linskens

Pharmaceuticals & Biotech

Manufacturing Site Divestitures: Best Practices for Successful Execution

by Michelle Carr, Daniel Garcia, Lois Sheng Liu and Xin Tao

Digital Health

Medical Device AI in Limbo: EU’s Digital Overhaul or Digital Headache for Pharma and Medtech?

by Jaspreet Takhar and Julia Gillert

Medical Devices

EU Biotech Act Unveiled: Commission’s Proposal to Turn Europe into a Biotech Powerhouse

by Baker McKenzie - HiH Blog

United States: President Trump Tariffs on Patented Pharmaceuticals Under Section 232

Medical Devices December 19, 2025

The EU’s 2025 proposal to simplify the Medical and In-Vitro-Diagnostic Devices Regulations (MDR/IVDR)

On 16 December 2025, the European Commission published its proposal to simplify the EU’s Medical Devices Regulation (Regulation (EU) 2017/745) (MDR) and In Vitro…

EU Pharmaceutical Package December 11, 2025

EU Pharma Package: A Landmark Political Deal Sealed

In the early morning of 11 December 2025, the Council and European Parliament reached a political agreement on the overhaul of the general EU…

Medical Devices November 10, 2025

Healthcare & Life Sciences Supply Chains Series: Opportunities for Innovators, Investors and Strategic Partners (4 of 4)

Tariffs and shifting trade dynamics continue to disrupt healthcare and life sciences supply chains. But in addition to affecting operational and commercial outlooks for…

Subscribe for Regular Alerts
<a href=https://bakerxchange.com/s/c52fd01a1d26bb8596eb85be3f6666b83a7d2dc5>View Survey</a>
Related Websites
HLS HUB
Archives
Archives

EU Pharmaceutical Package

In EU Pharmaceutical Package

A New Dawn for the EU Pharma Regulatory Regime? The Commission’s Proposal to Revise the EU Pharmaceutical Legislation is Finally Published

April 26, 2023 by Els Janssens, Magda Tovar and Julia Gillert 5 Mins Read

Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…

In EU Pharmaceutical Package

EU Pharma Package: How Significant are the Proposals for Orphan Medicines?

May 16, 2023 by Els Janssens, Magda Tovar and Julia Gillert 6 Mins Read

On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…

In EU Pharmaceutical Package

Hungarian Pricing and Reimbursement Reforms Aiming to Remove Hurdles to Late Market Access of Innovative Pharmaceuticals

May 26, 2023 by Dr. Helga Bíró M.Jur. and Máté Laczkó 3 Mins Read

In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…

In EU Pharmaceutical Package

The EU Pharmaceutical Package From a National Perspective: Member States’ First Reactions

May 30, 2023 by Els Janssens, Julie Yeni, Dr. Martin Altschwager LL.M., Dr. Frank Pflueger and Magda Tovar 6 Mins Read

The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…

In EU Pharmaceutical Package

The Future is Green: Eco Measures are Embedded into the EU Reform Proposals

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 2 Mins Read

As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…

In EU Pharmaceutical Package

Supply Chain Protection: What do the EU Reform Proposals Look Like and do They go Far Enough?

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 3 Mins Read

As already well noted on this blog, on 26 April 2023 the European Commission published a set of…